Fink AM, et al. - Lenalidomide maintenance therapy was appraised in patients with chronic lymphocytic leukaemia with poor outcome after first-line chemoimmunotherapy. Reducing the relative risk of progression in this group of patients, the recommended regimen was an efficacious maintenance therapy. Moreover, the trial independently confirmed the clinical significance of a novel, minimal residual disease-based algorithm to predict short progression-free survival.